目的 觀察平消膠囊聯(lián)合FOLFOX4化療方案對大腸癌患者術(shù)后臨床療效、生活質(zhì)量及免疫功能的影響。方法 選取襄陽市中心醫(yī)院2013年6月—2014年12月大腸癌病例96例, 隨機分為治療組(48例)和對照組(48例)。對照組給予FOLFOX4方案化療, 注射用奧沙利鉑130 mg/m², 1次/d, 持續(xù)靜脈滴注, 3 h內(nèi)滴完, 第1天;注射用亞葉酸鈣100 mg/m², 1次/d, 靜脈滴注, 第1~5天;氟尿嘧啶注射液600 mg/m², 1次/d, 靜脈滴注, 24 h持續(xù)滴注, 或至少6 h以上滴完, 第1~5天。治療組給予FOLFOX4方案化療, 并于化療第1天開始給予平消膠囊8粒/次, 3次/d。3周為1個療程, 連續(xù)觀察4個療程。比較兩組患者的臨床療效、生活質(zhì)量、體質(zhì)量、免疫功能和毒副反應(yīng)。結(jié)果 治療組有效率為91.67%, 對照組有效率為79.17%, 兩組有效率比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療組KPS評分改善率為87.50%, 對照組KPS評分改善率為70.85%, 兩組KPS評分改善率比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療組體質(zhì)量改善率為91.7%, 對照組體質(zhì)量改善率為62.5%, 兩組體質(zhì)量改善率比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后治療組CD³⁺、CD⁴⁺、CD⁴⁺/CD⁸⁺、NK細(xì)胞明顯升高, CD⁸⁺明顯降低, 與治療前比較差異具有統(tǒng)計學(xué)意義(P<0.05、0.01), 與對照組治療后比較差異具有統(tǒng)計學(xué)意義(P<0.05)。治療后治療組IgG、IgM水平較治療前明顯升高(P<0.01), 與對照組比較差異具有統(tǒng)計學(xué)意義(P<0.05)。結(jié)論 平消膠囊聯(lián)合FOLFOX4方案化療對大腸癌術(shù)后患者的生活質(zhì)量、體質(zhì)量變化療效均明顯優(yōu)于單純化療, 可顯著增強患者術(shù)后早期機體免疫功能, 提高生活質(zhì)量, 有很好的臨床應(yīng)用價值。

Objective To observe the impact of Pingxiao Capsules combined with FOLFOX4 scheme on clinical efficacy, quality of life, and immune function among patients with colorectal cancer after operation. Methods The 96 cases of colorectal cancer patients admitted to Xiangyang Central Hospital from June 2014 to December 2013 were randomly divided into the control group and the treatment group, and each group had 48 cases. The control group was treated with FOLFOX4 scheme (including oxaliplatin, Calcium folic acid, and fluorouracil) conventional chemotherapy. The patients in the control group were iv administered with Oxaliplatin for injection 130 mg/m², once daily, intravenous dripping within 3 h in the first day. And then they were iv administered with Calcium folic acid for injection 100 mg/m², once daily, intravenous dripping from the first day to the fifth day. Finally Fluorouracil Injection was iv administered 600 mg/m², once a day, continuous intravenous drip for 24 h continuous infusion, or at least more than 6 h drops, from first day to fifth day. The treatment group was given Pingxiao Capsules at the basis of chemotherapy for the first day, 8 capsules / time, three times daily. One course of treatment was 3 weeks. After four courses of treatment, changes in efficacy, quality of life, weight change, immune function, and toxicity in two groups were compared. Results After treatment, the efficacies in the treatment and control groups were 91.67% and 79.17%, respectively, and there were differences between two groups (P < 0.05). The KPS score improvement rates of the treatment and control groups were 87.50% and 70.85%, respectively, and the differences were statistically significant between two groups (P < 0.05). The body weight improvement rates of the treatment and control groups were 91.7% and 62.5%, respectively, with significant differences between two groups (P < 0.05). After treatment, CD³⁺, CD⁴⁺, CD⁴⁺/CD⁸⁺, and NK cells were significantly increased, but CD⁸⁺ in two groups significantly reduced, and the difference was statistically significant in the same group (P < 0.05, 0.01). Compared with the control group, these indicators in treatment group improved better, with significant differences between two groups (P < 0.05). After treatment, the levels of IgG and IgM were significantly increased, and the difference was statistically significant in the same group (P < 0.01). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). Conclusion Pingxiao Capsules combined with the chemotherapy of FOLFOX scheme for patients with colorectal cancer after operation is significantly better than patients treated with chemotherapy in enhancing early immune function of colorectal cancer patients undergoing postoperative chemotherapy, improving quality of life, which has a good clinical value.